You are here

Article info

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Short report
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies

Authors

  • Joseph Kauer Department of Immunology, University of Tübingen Interfaculty Institute of Cell Biology, Tubingen, Germany German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany, Tübingen, Germany DFG Cluster of Excellence 2180, 'Image-guided and Functional Instructed Tumor Therapy' (IFIT), University of Tübingen, Tübingen, Germany, Tübingen, Germany Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Sebastian Hörner Department of Immunology, University of Tübingen Interfaculty Institute of Cell Biology, Tubingen, Germany German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Lukas Osburg Department of Immunology, University of Tübingen Interfaculty Institute of Cell Biology, Tubingen, Germany German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Stefanie Müller DFG Cluster of Excellence 2180, 'Image-guided and Functional Instructed Tumor Therapy' (IFIT), University of Tübingen, Tübingen, Germany, Tübingen, Germany Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Melanie Märklin DFG Cluster of Excellence 2180, 'Image-guided and Functional Instructed Tumor Therapy' (IFIT), University of Tübingen, Tübingen, Germany, Tübingen, Germany Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Jonas S Heitmann DFG Cluster of Excellence 2180, 'Image-guided and Functional Instructed Tumor Therapy' (IFIT), University of Tübingen, Tübingen, Germany, Tübingen, Germany Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Latifa Zekri Department of Immunology, University of Tübingen Interfaculty Institute of Cell Biology, Tubingen, Germany German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Hans-Georg Rammensee Department of Immunology, University of Tübingen Interfaculty Institute of Cell Biology, Tubingen, Germany German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany, Tübingen, Germany DFG Cluster of Excellence 2180, 'Image-guided and Functional Instructed Tumor Therapy' (IFIT), University of Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Helmut R Salih DFG Cluster of Excellence 2180, 'Image-guided and Functional Instructed Tumor Therapy' (IFIT), University of Tübingen, Tübingen, Germany, Tübingen, Germany Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Gundram Jung Department of Immunology, University of Tübingen Interfaculty Institute of Cell Biology, Tubingen, Germany German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Tübingen, Germany, Tübingen, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Gundram Jung; gundram.jung{at}uni-tuebingen.de
View Full Text

Citation

Kauer J, Hörner S, Osburg L, et al
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
Journal for ImmunoTherapy of Cancer 2020;8:e000621. doi: 10.1136/jitc-2020-000621

Publication history

  • Accepted April 9, 2020
  • First published May 30, 2020.
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.